Relevant bibliographies by topics / Nontuberculous mycobacterial pulmonary disease

Academic literature on the topic 'Nontuberculous mycobacterial pulmonary disease'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Nontuberculous mycobacterial pulmonary disease.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Nontuberculous mycobacterial pulmonary disease"

1

Falkinham, Joseph O. "The Changing Pattern of Nontuberculous Mycobacterial Disease." Canadian Journal of Infectious Diseases 14, no. 5 (2003): 281–86. http://dx.doi.org/10.1155/2003/323058.

Full text
Abstract:
Nontuberculous mycobacteria are human opportunistic pathogens whose source of infection is the environment. These include both slow-growing (eg,Mycobacterium kansasii and Mycobacterium avium) and rapid-growing (eg,Mycobacterium abscessusandMycobacterium fortuitum) species. Transmission is through ingestion or inhalation of water, particulate matter or aerosols, or through trauma. The historic presentation of pulmonary disease in older individuals with predisposing lung conditions and in children has been changing. Pulmonary disease in elderly individuals who lack the classic predisposing lung conditions is increasing. Pulmonary disease and hypersensitivity pneumonitis have been linked with occupational or home exposures to nontuberculous mycobacteria. There has been a shift fromMycobacterium scrofulaceumtoM aviumin children with cervical lymphadenitis. Further, individuals who are immunosuppressed due to therapy or HIV-infection are at a greatly increased risk for nontuberculous mycobacterial infection. The changing pattern of nontuberculous mycobacterial disease is due in part to the ability of these pathogens to survive and proliferate in habitats that they share with humans, such as drinking water. The advent of an aging population and an increase in the proportion of immunosuppressed individuals suggest that the prevalence of nontuberculous mycobacterial disease will increase.
APA, Harvard, Vancouver, ISO, and other styles
2

Jarzembowski, Jason A., and Michael B. Young. "Nontuberculous Mycobacterial Infections." Archives of Pathology & Laboratory Medicine 132, no. 8 (August 1, 2008): 1333–41. http://dx.doi.org/10.5858/2008-132-1333-nmi.

Full text
Abstract:
Abstract Context.—Nontuberculous mycobacteria include numerous acid-fast bacilli species, many of which have only recently been recognized as pathogenic. The diagnosis of mycobacterial disease is based on a combination of clinical features, microbiologic data, radiographic findings, and histopathologic studies. Objective.—To provide an overview of the clinical and pathologic aspects of nontuberculous mycobacteria infection, including diagnostic laboratory methods, classification, epidemiology, clinical presentation, and treatment. Data Sources.—Review of the pertinent literature and published methodologies. Conclusions.—Nontuberculous mycobacteria include numerous acid-fast bacilli species, many of which are potentially pathogenic, and are classified according to the Runyon system based on growth rates and pigment production. Their slow growth hinders cultures, which require special medium and prolonged incubation. Although such methods are still used, newer nucleic acid–based technologies (polymerase chain reaction and hybridization assays) can rapidly detect and speciate some mycobacteria—most notably, distinguishing Mycobacterium tuberculosis from other species. Infections caused by these organisms can present as a variety of clinical syndromes, not only in immunocompromised patients but also in immunocompetent hosts. Most common among these are chronic pulmonary infections, superficial lymphadenitis, soft tissue and osteoarticular infections, and disseminated disease. Treatment of nontuberculous mycobacterial infections is difficult, requiring extended courses of multidrug therapy with or without adjunctive surgical intervention.
APA, Harvard, Vancouver, ISO, and other styles
3

Kim, Richard D., David E. Greenberg, Mary E. Ehrmantraut, Shireen V. Guide, Li Ding, Yvonne Shea, Margaret R. Brown, et al. "Pulmonary Nontuberculous Mycobacterial Disease." American Journal of Respiratory and Critical Care Medicine 178, no. 10 (November 15, 2008): 1066–74. http://dx.doi.org/10.1164/rccm.200805-686oc.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Cowman, Steven, and Michael Loebinger. "Nontuberculous Mycobacterial Pulmonary Disease." Clinical Pulmonary Medicine 22, no. 1 (January 2015): 8–14. http://dx.doi.org/10.1097/cpm.0000000000000079.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Johnson, Margaret M., Ernest Andrew Waller, and Jack P. Leventhal. "Nontuberculous mycobacterial pulmonary disease." Current Opinion in Pulmonary Medicine 14, no. 3 (May 2008): 203–10. http://dx.doi.org/10.1097/mcp.0b013e3282f9e650.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Salzer, Helmut J. F., Bakari Chitechi, Doris Hillemann, Michael Mandl, Christian Paar, Monika Mitterhumer, Bernd Lamprecht, and Florian P. Maurer. "Nontuberculous Mycobacterial Pulmonary Disease from Mycobacterium hassiacum, Austria." Emerging Infectious Diseases 26, no. 11 (November 2020): 2776–78. http://dx.doi.org/10.3201/eid2611.191718.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Banaschewski and Hofmann. "Inhaled Antibiotics for Mycobacterial Lung Disease." Pharmaceutics 11, no. 7 (July 19, 2019): 352. http://dx.doi.org/10.3390/pharmaceutics11070352.

Full text
Abstract:
Mycobacterial lung diseases are an increasing global health concern. Tuberculosis and nontuberculous mycobacteria differ in disease severity, epidemiology, and treatment strategies, but there are also a number of similarities. Pathophysiology and disease progression appear to be relatively similar between these two clinical diagnoses, and as a result these difficult to treat pulmonary infections often require similarly extensive treatment durations of multiple systemic drugs. In an effort to improve treatment outcomes for all mycobacterial lung diseases, a significant body of research has investigated the use of inhaled antibiotics. This review discusses previous research into inhaled development programs, as well as ongoing research of inhaled therapies for both nontuberculous mycobacterial lung disease, and tuberculosis. Due to the similarities between the causative agents, this review will also discuss the potential cross-fertilization of development programs between these similar-yet-different diseases. Finally, we will discuss some of the perceived difficulties in developing a clinically utilized inhaled antibiotic for mycobacterial diseases, and potential arguments in favor of the approach.
APA, Harvard, Vancouver, ISO, and other styles
8

Cowman, Steven A., Phillip James, Robert Wilson, William O. C. Cookson, Miriam F. Moffatt, and Michael R. Loebinger. "Profiling mycobacterial communities in pulmonary nontuberculous mycobacterial disease." PLOS ONE 13, no. 12 (December 11, 2018): e0208018. http://dx.doi.org/10.1371/journal.pone.0208018.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Velagapudi, Manasa, Michael J. Sanley, Sumaya Ased, Chris Destache, and Mark A. Malesker. "Pharmacotherapy for nontuberculous mycobacterial pulmonary disease." American Journal of Health-System Pharmacy 79, no. 6 (November 11, 2021): 437–45. http://dx.doi.org/10.1093/ajhp/zxab422.

Full text
Abstract:
Abstract Purpose To provide an updated review of the diagnosis and pharmacotherapy of nontuberculous mycobacteria pulmonary disease (NTM-PD) and summarize guideline recommendations for an interdisciplinary treatment approach. Summary A systemic approach was taken in which all articles in English in MEDLINE and PubMed were reviewed. The US National Library of Medicine's DailyMed database was used to assess drug package inserts. Analysis of NTM treatment guidelines is summarized in the article with a focus on medications, dosing, interactions, and medication monitoring. Conclusion It is critical to manage patients with NTM with a multidisciplinary team approach. Treatment is prolonged and expensive, and the potential for drug toxicity, adverse effects, and drug interactions requires monitoring. Clinical pharmacists play a role in the management of NTM.
APA, Harvard, Vancouver, ISO, and other styles
10

Adelman, Mark H., and Doreen J. Addrizzo-Harris. "Management of nontuberculous mycobacterial pulmonary disease." Current Opinion in Pulmonary Medicine 24, no. 3 (May 2018): 212–19. http://dx.doi.org/10.1097/mcp.0000000000000473.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Nontuberculous mycobacterial pulmonary disease"

1

Fowler, Cedar. "Identification of a ciliary defect associated with pulmonary nontuberculous mycobacterial disease." Thesis, University of Cambridge, 2013. https://www.repository.cam.ac.uk/handle/1810/245062.

Full text
Abstract:
Over the past several decades, the rate of pulmonary nontuberculous my- cobacterial (PNTM) disease has been increasing. PNTM patients gener- ally consist of lean and tall women presenting with symptoms in the sixth decade of life. They have a de nitive morphophenotype, but no consistent immunological abnormalities despite extensive investigation. I hypothesized that respiratory epithelial dysfunction might play a critical role in PNTM disease predisposition because diseases with defects of mucociliary transport have high rates of PNTM disease that increase with age, suggesting a direct connection between airway epithelial function and PNTM disease. I found that PNTM patients have a distinct respiratory epithelial phenotype ex vivo and decreased nasal nitric oxide levels in vivo. The PNTM ex vivo phenotype consists of an abnormally low resting ciliary beat frequency (CBF) and abnormal CBF response to toll-like receptor (TLR) agonists. The depressed baseline CBF response in PNTM patient cells can be normalized ex vivo by augmenting the nitric oxide-cyclic guanosine monophosphate pathway without appreciable e ect on CBF in healthy controls. In healthy controls, bacterial TLR agonists increase CBF and viral TLR agonists decrease CBF. In PNTM patients these responses are impaired and are not normalized with the normalization of the resting CBF rate. Inhibitor-induced disruption of signalling pathways associated with CBF regulation demonstrated that the majority of the CBF response to TLR agonists involves the PI-3K pathway and PKC. Inhibition of the PI-3K pathway (PI-3K , Akt1, and PDK1) closely mimicked the ex vivo phenotype seen in PNTM patient respiratory epithelia. These data identify a novel aspect of PNTM disease with in vivo and ex vivo correlates that suggest that PNTM infection is associated with abnormal function at both the CBF and TLR response levels. This phenotype is novel, reproducible, and provide a foundation with which to determine the genetic basis of PNTM infection.
APA, Harvard, Vancouver, ISO, and other styles
2

Afshan, Kiran. "Extra pulmonary Nontuberculous Mycobacterial Infections 16 Year Retrospective Analysis at an Academic Institution in Cincinnati Ohio." University of Cincinnati / OhioLINK, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1504869625635459.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Brittle, Wendy. "The optimisation of laboratory cultivation in childhood mycobacterial disease in South Africa." Thesis, [S.l. : s.n.], 2009. http://dk.cput.ac.za/cgi/viewcontent.cgi?article=1071&context=td_cput.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Pascoal, Mariana Santos. "Mycobacterium Kansasii pulmonary disease in a patient with risk factors: case report." Master's thesis, 2020. http://hdl.handle.net/10316/97690.

Full text
Abstract:
Trabalho Final do Mestrado Integrado em Medicina apresentado à Faculdade de Medicina
Mycobacterium kansasii é uma das micobactérias não tuberculosas mais relevantes e a sua incidência tem vindo a aumentar em todo o mundo. Doença pulmonar estrutural e tuberculose pulmonar prévia são fatores de risco. Doentes asmáticos apresentam também maior incidência da infeção. Doentes com hipertensão pulmonar apresentam uma incidência semelhante à verificada noutras doenças pulmonares crónicas consideradas fatores de risco. Descrevemos o caso de uma doente de 46 anos com vários de fatores de risco para a infeção e comorbilidades, que no dia 31 de Outubro de 2018 numa angiografia por tomografia computorizada apresentava uma cavitação no lobo superior esquerdo e uma baciloscopia positiva na expetoração. A doente apresentava tosse produtiva persistente com expetoração mucopurulenta há 4 meses. Os seus antecedentes incluíam tuberculose pulmonar, asma brônquica e hipertensão pulmonar tipo IV. O contexto epidemiológico era irrelevante. O tratamento quadruplo foi iniciado e, mais tarde, a pirazinamida foi removida aquando a identificação de Mycobacterium kansasii, por amplificação de ácidos nucleicos. Em Outubro de 2019, a baciloscopia negativou e a cavitação apresentou resolução total.Concluindo, a incidência da infeção por micobactérias não tuberculosas está a aumentar e deve ser considerada na nossa prática clínica em doentes com fatores de risco. .
Mycobacterium kansasii is one of the most relevant non-tuberculous mycobacteria and its incidence has increased all over the world. The risk factors include structural lung disease and prior pulmonary tuberculosis. Asthmatic patients seem to have a higher infection prevalence. The incidence in pulmonary hypertension patients is identical to in other chronic pulmonary diseases considered to be risk groups. We described the case of a 46 year-old patient with an unusual combination of risk factors and comorbidities that presented at 31st October 2018 with a cavitation on the upper left lobe detected in a routine computed tomography angiography and a positive bacilli detection in sputum smear microscopy. She reported persistent productive cough with mucopurulent sputum, in the past 4 months. Her medical history included pulmonary tuberculosis, bronchial asthma, and pulmonary hypertension type IV. Epidemiological context was irrelevant. Four-drug regimen treatment was initiated and later pyrazinamide was removed when the Mycobacterium kansasii was identified by nucleic acid amplification. Bacilloscopy and the cavitation on the X-ray showed complete resolution in October 2019. In conclusion, the incidence of non-tuberculous bacteria’s infection is increasing and it must be considered in all patients with risk factors in our clinical practice. .
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Nontuberculous mycobacterial pulmonary disease"

1

Griffith, David E., ed. Nontuberculous Mycobacterial Disease. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-93473-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Thomas, Charles F., and Sean M. Caples. Pulmonary Infections. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780199755691.003.0619.

Full text
Abstract:
Different types of infections affect the lungs. Viral infections include viral pneumonia, influenza, hantavirus, severe acute respiratory syndrome (SARS). Bacterial infections include sinusitis, otitis media, pharyngitis, bacterial pneumonia, and community-acquired pneumonia. Mycobacterial infections cause tuberculosis and nontuberculous mycobacterial disease. Fungal diseases include histoplasmosis, blastomycosis, cryptococcosis, coccidioidomycosis, and aspergillosis. Parasitic lung disease is also reviewed.
APA, Harvard, Vancouver, ISO, and other styles
3

Antonino, Catanzaro, and Daley Charles L, eds. Lung disease due to nontuberculous mycobacterial infections. Philadelphia: Saunders, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Griffith, David E. Nontuberculous Mycobacterial Disease: A Comprehensive Approach to Diagnosis and Management. Humana, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Griffith, David E. Nontuberculous Mycobacterial Disease: A Comprehensive Approach to Diagnosis and Management. Springer, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Stowell, Janet, and Ronan Breen. Pulmonary disease caused by non-tuberculous mycobacteria. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199657742.003.0014.

Full text
Abstract:
This chapter describes a case of Mycobacterium malmoense in a male ex-smoker with chronic obstructive pulmonary disease. The approaches to a diagnosis of pulmonary non-tuberculous mycobacterial disease are discussed, including key laboratory features and associated radiological changes. The factors influencing the decision to treat and treatment regimen selected are reviewed, along with evidence from landmark trials regarding drug combinations and the role of surgery in managing non-tuberculous mycobacterial disease. This case was complicated by a secondary diagnosis of invasive aspergillosis, and the challenges of treating non-tuberculous mycobacteria and Aspergillus concurrently are highlighted. Non-tuberculous mycobacterial infection in HIV-positive patients can behave differently to non-tuberculous mycobacterial disease in immunocompetent individuals. Restoring immunocompetence is key to the success of non-tuberculous mycobacterial treatment in these individuals, but beware Mycobacterium avium complex-related immune restoration inflammatory syndrome.
APA, Harvard, Vancouver, ISO, and other styles
7

D, Mitchell John. Surgery for Pulmonary Mycobacterial Disease, an Issue of Thoracic Surgery Clinics. Elsevier, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Eastwood, John, Cathy Corbishley, and John Grange. Mycobacterial infections. Edited by Vivekanand Jha. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0196.

Full text
Abstract:
The genus Mycobacterium contains over a hundred species including the M. tuberculosis complex and M. leprae, the causative agents of, respectively, tuberculosis and leprosy. The many other species are environmental saprophytes, present particularly in free and piped water sources, and some species are causes of opportunist disease in humans, especially in those who are immune compromised.The genitourinary tract is a common site of both primary and post-primary tuberculosis. In most cases of renal tuberculosis there are gross lesions consisting of caseating granulomas from which tubercle bacilli enter the urinary tract, often with the development of secondary lesions in the ureters, bladder, epididymis, and testis. Tuberculous interstitial nephritis is a less common condition with an insidious course and may result in renal failure. The urine is often negative for tubercle bacilli, emphasizing the need for biopsy in those with renal insufficiency.The risk of developing pulmonary or disseminated tuberculosis after infection is greatly enhanced by any form of immune compromise including renal failure and post-renal transplant immunosuppression.
APA, Harvard, Vancouver, ISO, and other styles
9

Aston, Stephen, Geraint Davies, and Nick Beeching. Mycobacterial infection other than tuberculosis. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0311.

Full text
Abstract:
Mycobacteria are aerobic bacilli with a lipid-rich cell wall and are widespread both in the environment and in animals. Many species within the genus cause disease in humans, most notably those of the Mycobacterium tuberculosis complex, which cause tuberculosis, and Mycobacterium leprae, the causative agent of leprosy. Several other species, termed non-tuberculous mycobacteria, can cause chronic cutaneous, pulmonary, and disseminated infections. This chapter will briefly review infection with non-tuberculous mycobacteria and Mycobacterium leprae.
APA, Harvard, Vancouver, ISO, and other styles
10

Kosmidis, Chris, David W. Denning, and Eavan G. Muldoon. Fungal disease in cystic fibrosis and chronic respiratory disorders. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0037.

Full text
Abstract:
A range of fungal disease syndromes affect patients with chronic respiratory diseases and cystic fibrosis (CF). Invasive aspergillosis is increasingly recognized in seriously ill patients with chronic obstructive pulmonary disease, especially after high-dose steroids. Chronic pulmonary aspergillosis affects patients with pre-existing cavities or bullae, such as those with previous tuberculosis or atypical mycobacterial disease, bullous emphysema, sarcoidosis, pneumothorax, or treated lung cancer. In addition, fungi have become one of the most important trigger agents for asthma, and allergic bronchopulmonary aspergillosis may complicate up to 3.5% of cases of asthma and up to 15% of cases of CF, starting in childhood. CF patients are commonly colonized with fungal organisms, although the impact of such colonization on outcome is not clear. Aspergillus is the most common mould isolated from CF patients. Distinguishing between colonization and infection remains challenging. Candida is thought to be of no clinical significance; however, it has been associated with decline in lung function.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Nontuberculous mycobacterial pulmonary disease"

1

Clain, Jeremy M., and Timothy R. Aksamit. "Diagnosis of NTM Disease: Pulmonary and Extrapulmonary." In Nontuberculous Mycobacterial Disease, 261–70. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-93473-0_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Daniel-Wayman, Shelby, Jennifer Adjemian, and D. Rebecca Prevots. "Epidemiology of Nontuberculous Mycobacterial Pulmonary Disease (NTM PD) in the USA." In Nontuberculous Mycobacterial Disease, 145–61. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-93473-0_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

O’Brien, Richard J., and David L. Cohn. "Nontuberculous Mycobacterial Disease." In Bacterial Infections of Humans, 805–21. Boston, MA: Springer US, 1998. http://dx.doi.org/10.1007/978-1-4615-5327-4_41.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

O’Brien, Richard J., and George W. Comstock. "Nontuberculous Mycobacterial Disease." In Bacterial Infections of Humans, 773–86. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4757-1211-7_37.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Griffith, David E. "Nontuberculous Mycobacterial Disease: An Introduction and Historical Perspective." In Nontuberculous Mycobacterial Disease, 1–14. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-93473-0_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Aksamit, Timothy R., and David E. Griffith. "Nontuberculous Mycobacterial Disease Management Principles." In Nontuberculous Mycobacterial Disease, 271–99. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-93473-0_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Holt, Michael R., and Charles L. Daley. "Mycobacterium avium Complex Disease." In Nontuberculous Mycobacterial Disease, 301–23. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-93473-0_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Marras, Theodore K., and Sarah K. Brode. "NTM Disease Caused by M. kansasii, M. xenopi, M. malmoense, and Other Slowly Growing NTM." In Nontuberculous Mycobacterial Disease, 325–68. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-93473-0_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Philley, Julie V., and David E. Griffith. "Disease Caused by Mycobacterium Abscessus and Other Rapidly Growing Mycobacteria (RGM)." In Nontuberculous Mycobacterial Disease, 369–99. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-93473-0_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

O’Donnell, Anne E. "Management of Lung Diseases Associated with NTM Infection." In Nontuberculous Mycobacterial Disease, 401–11. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-93473-0_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Nontuberculous mycobacterial pulmonary disease"

1

Janković Makek, Mateja, Goran Glodic, Ivan Sabol, Ljiljana Zmak, Ana-Marija Sola, Ante Marusic, Ivana Marekovic, et al. "Cure rates in nontuberculous mycobacterial pulmonary disease." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa4645.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Okamori, Satoshi, Eisaku Tanaka, Nobuyoshi Hamao, Yuto Yasuda, Takashi Inao, Chie Morimoto, Ikkou Yasuda, et al. "Nontuberculous mycobacterial infection in chronic obstructive pulmonary disease." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa569.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Namkoong, Ho, Atsuyuki Kurashima, Kozo Morimoto, Yoshihiko Hoshino, Ato Manabu, Satoshi Mitarai, and Naoki Hasegawa. "The Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease in Japan." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.oa1972.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Goto, Y., Y. Yamano, T. Yokoyama, T. Matsuda, K. Kataoka, T. Kimura, and Y. Kondoh. "Nontuberculous Mycobacterial Pulmonary Disease in Patients with Interstitial Pneumonia." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2525.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Williams, M., R. A. Blakney, S. Lee, R. Prevots, R. M. Summers, K. N. Olivier, and K. P. Fennelly. "Sarcopenia and Myosteatosis in Pulmonary Nontuberculous Mycobacterial Disease Outcomes." In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3880.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kumar, K., L. Cuthbertson, HC Ellis, C. Churchward, MR Loebinger, MF Moffatt, and WOC Cookson. "S54 The lung microbiome in nontuberculous mycobacterial pulmonary disease." In British Thoracic Society Winter Meeting 2022, QEII Centre, Broad Sanctuary, Westminster, London SW1P 3EE, 23 to 25 November 2022, Programme and Abstracts. BMJ Publishing Group Ltd and British Thoracic Society, 2022. http://dx.doi.org/10.1136/thorax-2022-btsabstracts.60.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mizutani, Rafael Futoshi, Elisa Maria Siqueira Lombardi, Ubiratan de Paula Santos, and Mário Terra-Filho. "Silica exposure, silicosis, autoimmune diseases, tuberculosis and nontuberculous pulmonary mycobacterial disease." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa1171.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Asakura, Takanori, Nobutaka Hayakawa, Naoki Hasegawa, Ho Namkoong, Ken Takeuchi, Shoji Suzuki, Makoto Ishii, Tomoko Betsuyaku, Yoshiaki Abe, and Motofumi Ouchi. "Long-term Outcome of Pulmonary Resection for Nontuberculous Mycobacterial Pulmonary Disease." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa4075.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Wix, Kelly, Laura Odell, Susan Fisher, and Timothy R. Aksamit. "Pharmacist-Physician Collaboration In Management Of Nontuberculous Mycobacterial Pulmonary Disease." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a2595.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mehta, Mauli, and Theodore K. Marras. "Health Related Quality Of Life In Pulmonary Nontuberculous Mycobacterial DISEASE." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a2598.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Nontuberculous mycobacterial pulmonary disease' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography